Twenty-Month Monitoring of Humoral Immune Response to BNT162b2 Vaccine: Antibody Kinetics, Breakthrough Infections, and Adverse Effects DOI Creative Commons
Jarosław Walory, Iza Książek, Michał Karyński

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(10), P. 1578 - 1578

Published: Oct. 10, 2023

Vaccination is one of the most effective life-saving medical interventions, and introduction SARS-CoV-2 vaccines was intended to prevent serious implications COVID-19. The objectives study were (i) observe humoral immune response BNT162b2 vaccine infection (mainly breakthrough infections), (ii) demonstrate persistence anti-SARS-CoV-2 antibodies over time in relation number received doses course infection, (iii) determine adverse effects after primary doses. To assess response, IgG IgA anti-S1 quantified by ELISA assays. In total, tests carried out seven times almost two years. We demonstrated strong immunogenicity (compared levels before vaccination, 150- 20-fold increases IgA, respectively) vaccine. Over time, we observed a systematic decline antibody levels, which may have contributed infections. Although they caused seroconversion similar booster, such patients fell more rapidly than re-vaccination. On other hand, individuals who did not receive booster(s) present returned pre-vaccination 20 months. commonly recognized injection site redness swelling. highly preventing severe outcomes COVID-19 should be performed regardless prior infection. Booster significantly enhance and, contrast those obtained remain longer.

Language: Английский

Interplay of inflammatory markers and anti-SARS-CoV-2 antibodies in COVID-19 mortality: A prospective cohort study DOI Creative Commons
Sylvia Mink, Heinz Drexel, Andreas Leiherer

et al.

International Journal of Infectious Diseases, Journal Year: 2024, Volume and Issue: 143, P. 107016 - 107016

Published: March 22, 2024

Despite high global vaccination coverage, it remains unclear how and anti-SARS-CoV-2 antibodies affect immune responses inflammation levels in patients with COVID-19. It is further whether the inflammatory response differs depending on antibody combination of COVID-19 affects mortality rates.

Language: Английский

Citations

2
Association between Lipid Levels, Anti-SARS-CoV-2 Spike Antibodies and COVID-19 Mortality: A Prospective Cohort Study DOI Open Access
Sylvia Mink,

Christoph H. Saely,

Matthias Frick

et al.

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(15), P. 5068 - 5068

Published: Aug. 1, 2023

Recent studies suggest that both lipid levels and anti-severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) antibody are associated with outcome in coronavirus disease 2019 (COVID-19). While parameters have separately been implicated the neutralization clearance of pathogens during severe infections, it is currently unclear whether interplay these affects COVID-19. We therefore aimed to determine there was a relationship between lipoproteins, anti-SARS-CoV-2 antibodies, COVID-19 mortality. In this prospective, multicenter cohort study, we recruited 1152 hospitalized patients from five hospitals. Total cholesterol (TC), LDL-C, HDL-C, triglycerides, spike antibodies were measured on hospital admission. The investigated endpoint in-hospital TC significantly lower non-survivors than survivors (mg/dL, 95%CI; 56.1, 50.4-61.8 vs. 72.6, 70.2-75.0, p < 0.001; 34.2, 31.7-36.8 38.1, 37.2-39.1, = 0.025; 139.3, 130.9-147.7 157.4, 54.1-160.6, 0.002). Mortality risk increased progressively (aOR 1.73, 1.30-2.31, 1.44, 1.10-1.88, 0.008; 1.49, 1.14-1.94, 0.001). rates varied 2.1% for high LDL-C 16.3% low 9.14, 95%CI 3.17-26.34, Accordingly, total mortality 15.0% 8.01, 2.77-23.18, combination serum strongly Patients combined exhibited highest rates.

Language: Английский

Citations

5
Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis DOI Creative Commons

Lichen Ouyang,

Gang Lei,

Yeli Gong

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: March 11, 2024

The immunogenicity of COVID-19 vaccines in patients with liver cirrhosis remains largely unknown. purpose this meta-analysis was to investigate the and compare humoral cellular immune responses following complete vaccination between healthy controls. A systematic literature search conducted PubMed, EMBASE, Web Science from 1 January 2020 22 August 2023. Sixteen studies 2127 were included. pooled seroconversion rate 92.4% (95% CI, 86.2%–96%, I2 = 90%) significant between-study heterogeneity. Moreover, elicited a higher response compensated as compared decompensated (RR 1.069, 95% 1.011–1.131, 17%, p .019). Additionally, 10 included for comparison analysis results showed that slightly lower controls 0.972, 0.955–0.989, 66%, .001). Meanwhile, RR vs. 0.678 0.563–0.817, 0, < .0001). Our demonstrated diminished cirrhosis. Patients particularly who have completed full-doses should receive continuous attention preemptive measures.

Language: Английский

Citations

1
COVID-19 and Fatty Liver Disorders DOI Open Access
Maria Guarino, Valentina Cossiga, Francesco Cutolo

et al.

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(13), P. 4316 - 4316

Published: June 27, 2023

In late 2019, the world was shaken by COVID-19 pandemic. Severe Acute Respiratory Syndrome Coronavirus—2 (SARS-CoV-2) infection became one of main causes illness and hospitalization worldwide, especially in subjects with metabolic comorbidities such as obesity, diabetes, or liver disease. This scenario crosses disorders’ “pandemic”, caused exponential spreading non-alcoholic fatty disease, which is now most prevalent cause chronic disease (CLD). The aim this review to analyze key factors relationship between spectrum disorders (FLD), terms molecular mechanisms clinical presentation can predict a more severe course infection. addition, will face change management FLD during pandemics, central role telemedicine, other interventions preventing treating these subjects.

Language: Английский

Citations

2
Twenty-month Monitoring of Humoral Immune Response to BNT162b2 Vaccine: Antibody Kinetics, Breakthrough Infections and Adverse Effects DOI Open Access
Jarosław Walory, Iza Książek, Michał Karyński

et al.

Published: Sept. 13, 2023

Background: Vaccination is one of the most effective life-saving medical interventions, and introduction SARS-CoV-2 vaccines was intended to prevent serious implications COVID-19. The objectives study were: i) observe humoral immune response BNT162b2 vaccine infection (mainly breakthrough infections), ii) demonstrate persistence anti-SARS-CoV-2 antibodies over time in relation number received doses course infection, iii) determine adverse effects after primary doses. Methods: To assess response, IgG IgA anti-S1 were quantified by ELISA assays. In total, tests carried out seven times almost two years. Results: We demonstrated strong immunogenicity (compared levels before vaccination, 150- 20-fold increases IgA, respectively) vaccine. Over time, we observed a systematic decline antibody levels, which may have contributed infections. Although they caused seroconversion similar booster, such patients fell more rapidly than re-vaccination. On other hand, individuals who did not receive booster(s) present returned pre-vaccination 20 months. commonly recognized injection site redness swelling. Conclusion: highly preventing severe outcomes COVID-19 should be performed regardless prior infection. Booster significantly enhance and, contrast those obtained remain longer.

Language: Английский

Citations

2
Twenty-Month Monitoring of Humoral Immune Response to BNT162b2 Vaccine: Antibody Kinetics, Breakthrough Infections, and Adverse Effects DOI Creative Commons
Jarosław Walory, Iza Książek, Michał Karyński

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(10), P. 1578 - 1578

Published: Oct. 10, 2023

Vaccination is one of the most effective life-saving medical interventions, and introduction SARS-CoV-2 vaccines was intended to prevent serious implications COVID-19. The objectives study were (i) observe humoral immune response BNT162b2 vaccine infection (mainly breakthrough infections), (ii) demonstrate persistence anti-SARS-CoV-2 antibodies over time in relation number received doses course infection, (iii) determine adverse effects after primary doses. To assess response, IgG IgA anti-S1 quantified by ELISA assays. In total, tests carried out seven times almost two years. We demonstrated strong immunogenicity (compared levels before vaccination, 150- 20-fold increases IgA, respectively) vaccine. Over time, we observed a systematic decline antibody levels, which may have contributed infections. Although they caused seroconversion similar booster, such patients fell more rapidly than re-vaccination. On other hand, individuals who did not receive booster(s) present returned pre-vaccination 20 months. commonly recognized injection site redness swelling. highly preventing severe outcomes COVID-19 should be performed regardless prior infection. Booster significantly enhance and, contrast those obtained remain longer.

Language: Английский

Citations

2